Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,407 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 2,407 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the transaction, the executive vice president owned 110,193 shares of the company’s stock, valued at $1,223,142.30. This represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, November 2nd, Vanina de Verneuil sold 1,343 shares of Vir Biotechnology stock. The stock was sold at an average price of $11.33, for a total transaction of $15,216.19.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded up $0.37 during trading on Wednesday, hitting $11.59. The company’s stock had a trading volume of 1,277,018 shares, compared to its average volume of 2,354,576. The stock has a 50-day moving average price of $10.99 and a two-hundred day moving average price of $9.53. Vir Biotechnology, Inc. has a 52 week low of $4.82 and a 52 week high of $12.19. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -6.23 and a beta of 1.70.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million for the quarter, compared to the consensus estimate of $135.88 million. Vir Biotechnology’s revenue was up 19582.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) earnings per share. On average, equities analysts predict that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Large investors have recently made changes to their positions in the business. Fiduciary Financial Advisors bought a new position in Vir Biotechnology during the 2nd quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Vir Biotechnology during the third quarter valued at about $97,000. Caxton Associates LLP bought a new position in Vir Biotechnology in the 1st quarter worth approximately $112,000. Amundi boosted its position in shares of Vir Biotechnology by 52.8% during the first quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after acquiring an additional 5,294 shares during the last quarter. Finally, Royal Bank of Canada grew its position in shares of Vir Biotechnology by 223.1% during the first quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock valued at $138,000 after purchasing an additional 10,603 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on VIR. Raymond James Financial reiterated a “strong-buy” rating on shares of Vir Biotechnology in a research report on Monday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Friday, October 2nd. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright increased their price objective on Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Morgan Stanley set a $25.00 price objective on Vir Biotechnology in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $21.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.